Low Doses of Imatinib Induce Myelopoiesis and Enhance Host Anti-microbial Immunity

Imatinib mesylate (Gleevec) inhibits Abl1, c-Kit, and related protein tyrosine kinases (PTKs) and serves as a therapeutic for chronic myelogenous leukemia and gastrointestinal stromal tumors. Imatinib also has efficacy against various pathogens, including pathogenic mycobacteria, where it decreases...

Descripción completa

Detalles Bibliográficos
Autores principales: Napier, Ruth J., Norris, Brian A., Swimm, Alyson, Giver, Cynthia R., Harris, Wayne A. C., Laval, Julie, Napier, Brooke A., Patel, Gopi, Crump, Ryan, Peng, Zhenghong, Bornmann, William, Pulendran, Bali, Buller, R. Mark, Weiss, David S., Tirouvanziam, Rabindra, Waller, Edmund K., Kalman, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379053/
https://www.ncbi.nlm.nih.gov/pubmed/25822986
http://dx.doi.org/10.1371/journal.ppat.1004770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379053/
https://www.ncbi.nlm.nih.gov/pubmed/25822986
http://dx.doi.org/10.1371/journal.ppat.1004770

Ejemplares similares